Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ContextVision ABOSL:CONTX +3.98%82 EV-to-EBITDA is 14.41 as of Jul. 27, 2026, which is 39% below its 10-year median of 23.55. GuruFocus rates OSL:CONTX with a GF Score™ of 82/100 and a GF Value™ of kr5.11 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 509 Healthcare Providers & Services companies, ContextVision AB ranks worse than 61.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ContextVision AB's enterprise value is kr196.9 Mil.
ContextVision AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr13.7 Mil. Therefore, ContextVision AB's EV-to-EBITDA for today is 14.41.
The historical rank and industry rank for ContextVision AB's EV-to-EBITDA or its related term are showing as below:
OSL:CONTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.57 Med: 23.55 Max: 272.68
Current: 14.41
During the past 13 years, the highest EV-to-EBITDA of ContextVision AB was 272.68. The lowest was 7.57. And the median was 23.55.
OSL:CONTX's EV-to-EBITDA is ranked worse than 61.89% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 10.97
vs OSL:CONTX: 14.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
ContextVision AB (OSL:CONTX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ContextVision AB's PE Ratio (TTM) for today is calculated as:
ContextVision AB's share price for today is kr3.40.
ContextVision AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.064.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ContextVision AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:CONTX vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, ContextVision AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ContextVision AB EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ContextVision AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ContextVision AB's EV-to-EBITDA falls into.
ContextVision AB's current Enterprise Value is kr196.9 Mil.
ContextVision AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr13.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContextVision AB (OSL:CONTX) has a EV-to-EBITDA of 14.41 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ContextVision AB. This is 39% below median its historical median of 23.55. Over the past decade, ContextVision AB's EV-to-EBITDA has ranged from 7.57 to 272.68. According to the industry distribution chart, ContextVision AB ranks #315 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 61.9%.
Is ContextVision AB's EV-to-EBITDA too high?
ContextVision AB's current EV-to-EBITDA of 14.41 is 39% below median its 10-year median of 23.55. Over the past 10 years, this metric has ranged from a low of 7.57 to a high of 272.68. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.97. ContextVision AB's value of 14.41 is 31.4% above this industry median. Based on the distribution chart, ContextVision AB ranks #315 out of 509 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, ContextVision AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ContextVision AB's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ContextVision AB ranks #315 out of 509 companies for EV-to-EBITDA. This places ContextVision AB in the lower half of its industry. The industry median EV-to-EBITDA is 10.97. ContextVision AB's value of 14.41 is 31.4% above this benchmark. Historically, ContextVision AB's own EV-to-EBITDA has ranged from 7.57 to 272.68 over the past decade. While the company's 10-year median is 23.55 vs. the industry median of 10.97, ContextVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.97, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ContextVision AB's current EV-to-EBITDA of 14.41 is 31.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ContextVision AB. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ContextVision AB's current EV-to-EBITDA is 14.41, which is 39% below median its own 10-year median of 23.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ContextVision AB stock overvalued right now?
Based on GuruFocus' analysis, ContextVision AB (OSL:CONTX) is currently considered Significantly Undervalued. The stock's GF Value™ is kr5.11, compared to a current price of kr3.40 — trading 33.5% below its estimated fair value. The current EV-to-EBITDA is 14.41, which is 39% below median its 10-year median of 23.55 and 31.4% above the Healthcare Providers & Services industry median of 10.97. ContextVision AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ContextVision AB (OSL:CONTX), the current EV-to-EBITDA is 14.41 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ContextVision AB (OSL:CONTX) Overvalued in 2026?
Based on GuruFocus' analysis, ContextVision AB stock appears to be undervalued.
The current stock price of kr3.40 is trading 33.5% below its estimated GF Value™ of kr5.11.
GuruFocus considers ContextVision AB to be Significantly Undervalued.
Key valuation signals for OSL:CONTX:
EV-to-EBITDA: 14.41 (39% below median its 10-year median of 23.55)
GF Value™: kr5.11 vs. price of kr3.40 (33.5% below fair value)
Industry Position: 31.4% above the Healthcare Providers & Services median (#315 of 509)
No single metric tells the full story. See the OSL:CONTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. Its geographical segments are Asia, Europe, and America.
82GF Score
Get the complete analysis for OSL:CONTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:CONTX has been successfully added to your 
